Literature DB >> 21463433

Recent surgical management of ovarian cancer.

Fady Khoury-Collado1, Dennis S Chi.   

Abstract

Ovarian cancer is the second most common gynecological malignancy in the USA, and the majority of patients with newly diagnosed ovarian cancer present with advanced-stage disease. The standard treatment of these patients involves primary cytoreduction followed by combination chemotherapy. As the evidence has accumulated regarding the benefit of surgical cytoreduction, and as the definition of optimal cytoreduction has evolved, the surgical techniques have expanded in order to achieve this goal. This article discusses the different facets of the surgical management of ovarian cancer, with a special emphasis on the most recent additions to our current knowledge.
© 2011 The Authors. Journal of Obstetrics and Gynaecology Research © 2011 Japan Society of Obstetrics and Gynecology.

Entities:  

Mesh:

Year:  2011        PMID: 21463433     DOI: 10.1111/j.1447-0756.2011.01569.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  3 in total

1.  Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer.

Authors:  S K Allensworth; C L Langstraat; J R Martin; M A Lemens; M E McGree; A L Weaver; S C Dowdy; K C Podratz; J N Bakkum-Gamez
Journal:  Gynecol Oncol       Date:  2013-06-05       Impact factor: 5.482

2.  Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study.

Authors:  Alaa A Elzarkaa; Waleed Shaalan; Doaa Elemam; Hassan Mansour; Mahmoud Melis; Eduard Malik; Amr A Soliman
Journal:  J Gynecol Oncol       Date:  2018-03-08       Impact factor: 4.401

3.  Ovarian cancer subtypes and survival in relation to three comprehensive imaging parameters.

Authors:  Hanna Sartor; Maria Bjurberg; Mihaela Asp; Anna Kahn; Jenny Brändstedt; Päivi Kannisto; Karin Jirström
Journal:  J Ovarian Res       Date:  2020-03-07       Impact factor: 4.234

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.